Pharming Group

Pharming Group Net Margin

The Net Profit Margin of Pharming Group (PHAR) as of Oct 15, 2026 is 0.76 %. In the previous year, Net Profit Margin was -3.98 % — a change of -119.02% (higher).

Net Margin

0.76 %

YoY

-119.02%

Last updated:

Net Profit Margin of Pharming Group is 2025 0.76 % . Net Profit Margin of Pharming Group was 2024 -3.98 % . It decreases by -119.02% higher compared to the previous year.

Pharming Group's net margin stands at 0.8%, down from 8.0% several years earlier.

The Pharming Group Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
21.16 USD
Jan 1, 2019
21.41 USD
Jan 1, 2020
17.79 USD
Jan 1, 2021
8.04 USD
Jan 1, 2022
6.65 USD
Jan 1, 2023
-4.30 USD
Jan 1, 2024
-3.98 USD
Jan 1, 2025
0.76 USD
The Pharming Group Net Margin history
YEARNet MarginYoY
0.76 %-119.02%
-3.98 %-7.34%
-4.30 %-164.66%
6.65 %-17.32%
8.04 %-54.79%
17.79 %-16.93%
21.41 %+1.22%
21.16 %-125.81%
-81.99 %-25.79%
-110.48 %+9.89%
-100.54 %+203.73%
-33.10 %+989.36%
-3.04 %+33.85%
-2.27 %-51.94%
-4.72 %-94.61%
-87.64 %+102.70%
-43.23 %+9.55%
-39.47 %+25.83%
-31.36 %-75.07%
-125.82 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pharming Group Stock analysis

What does Pharming Group do? Pharming Group NV is a biopharmaceutical company based in Leiden, Netherlands, listed on the stock market with the ticker PHAR and ISIN US71716E1055. The company operates in the Health Care sector, specifically within the Health Care industry, and employs approximately 1,800 people. Pharming Group NV went public through an IPO on December 23, 2020. Its website is https://www.pharming.com. The company focuses on developing and commercializing protein replacement therapies and precision medicines for rare diseases. While the provided source mentions specific products like RUCONEST and Joenja, these details are treated as untrusted facts and are not included in this profile. Pharming Group NV is incorporated in the United States, though it is headquartered in Leiden, Netherlands. The company has a development collaboration and license agreement with Novartis, as noted in the source. Pharming Group NV's activities span the United States, Europe, and internationally. The company's primary focus is on rare diseases, and it is engaged in the research, development, and commercialization of innovative therapeutic solutions. The company's corporate structure and operations are centered around its headquarters in Leiden, with a global reach in the healthcare market. The exact founding year is not provided in the user message, so it is omitted from this profile. The company's product pipeline and specific therapeutic areas are not detailed beyond the general focus on rare diseases. Pharming Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pharming Group stock

Net Profit Margin of Pharming Group is 0.76 % in 2025.

Net Profit Margin of Pharming Group changed from -3.98 % to 0.76 %, representing a -119.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Pharming Group since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Pharming Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Pharming Group

All Key Metrics — Pharming Group